Skip to main content
. 2020 Aug 21;18:587–601. doi: 10.1016/j.omto.2020.08.009

Figure 5.

Figure 5

Superior Efficacy of Combination Treatment of ICAM-1 CAR T Cells with Paclitaxel in an Intraperitoneal Xenograft Model

(A) Kaplan-Meier survival curves of untreated NSG mice intraperitoneally xenografted with different doses of SNU-638 cells (log-rank [Mantel-Cox] test; ∗∗p < 0.01; ns, not significant). (B) Whole-body bioluminescence images of SNU-638-engrafted NSG mice received either no treatment, or monotherapy with either T cells or paclitaxel, or combinatorial treatment. (C) Quantitation of total body bioluminescence intensity. Data represent mean ± SD (n = 5). (D) Kaplan-Meier survival curves (log-rank [Mantel-Cox] test; ∗p < 0.05, ∗∗p < 0.01; ns, not significant). (E) Representative PET/CT images of mice treated with ICAM-1 CAR T cells on 9 weeks post-xenograft (8 weeks after T cell injection). Coronal view of PET/CT images pseudo-colored with PET maximum intensity projection over a 20-mm-thick plane.